Bayer Hemophilia A Product Availability Status During Coronavirus (COVID-19) Outbreak:
Bayer Confirms All FVIII Hemophilia A Products Remain Available

The World Health Organization (WHO) has declared a Public Health Emergency of International Concern (PHEIC) in response to the 2019-nCoV (novel coronavirus) outbreak. Our thoughts are with the individuals and families that have been impacted by this virus.

We understand that consistent product availability is essential to people living with hemophilia A. Bayer wants to reassure healthcare providers and patients that rely on our hemophilia A products and associated infusion devices that we currently see no impact to product availability from our U.S. manufacturing operations. People with hemophilia A can use our products with confidence.

As the coronavirus outbreak is an evolving situation, we continue to monitor it and are in constant contact with our suppliers to address issues that may arise in our supply chain. Rest assured, we will keep patient advocacy organizations and health care providers informed of any material changes in status. Patients are encouraged to visit the website for the Bayer product that they are using.

For additional questions about our hemophilia A products and services, please contact Bayer Medical Communications at 888-842-2937.

©2020 Bayer
BAYER, the Bayer Cross are registered trademarks of Bayer